Fatal Thrombosis After Factor VII Administration During Extracorporeal Membrane Oxygenation

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 22, Issue 2, 2008, Pages 259-260

  Swaminathan, Madhav ^a   Shaw, Andrew D ^a   Greenfield, Ruth Ann ^a   Grichnik, Katherine P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

defibrillators; extracorporeal membrane oxygenation; factor VII; implantable; thoracic surgery

Indexed keywords

AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 7; FENTANYL; MIDAZOLAM; PROPOFOL; VECURONIUM;

ADULT; AORTA VALVE REGURGITATION; ARTICLE; BLEEDING; CARDIOMYOPATHY; CARDIOPULMONARY BYPASS; CASE REPORT; EXTRACORPOREAL OXYGENATION; FATAL THROMBOSIS; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HUMAN; LAPAROTOMY; MALE; PRIORITY JOURNAL; STERNOTOMY; TRANSTHORACIC ECHOCARDIOGRAPHY; VASCULAR DISEASE;

ADULT; EXTRACORPOREAL MEMBRANE OXYGENATION; FACTOR VII; FATAL OUTCOME; FEMALE; HUMANS; INTRAOPERATIVE COMPLICATIONS; THROMBOSIS;

EID: 41049092523     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2007.09.009     Document Type: Article

References (12)

1. Despotis G., Avidan M., and Lublin D.M. Off-label use of recombinant factor VIIA concentrates after cardiac surgery. Ann Thorac Surg 80 (2005) 3-5
2. Diprose P., Herbertson M.J., O'Shaughnessy D., et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebo-controlled pilot study. Br J Anaesth 95 (2005) 596-602
3. Oh J.J., Akers W.S., Lewis D., et al. Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy 26 (2006) 569-577
4. Pychynska-Pokorska M., Moll J.J., Krajewski W., et al. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 5 (2004) 246-250
5. Vanek T., Straka Z., Hrabak J., et al. Use of recombinant activated factor VII in cardiac surgery for an effective treatment of severe intractable bleeding. Jpn Heart J 45 (2004) 855-860
6. Yilmaz B.T., Alioglu B., Ozyurek E., et al. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol 26 (2005) 843-845
7. Shander A., Goodnough L.T., Ratko T., et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. Pharmacology Toxicology Pharamaceutics 30 (2005) 644-658
8. Warren O., Mandal K., Hadjianastassiou V., et al. Recombinant activated factor VII in cardiac surgery: A systematic review. Ann Thorac Surg 83 (2007) 707-714
9. Dominguez T.E., Mitchell M., Friess S.H., et al. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med 6 (2005) 348-351
10. Bui J.D., Despotis G.D., Trulock E.P., et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 124 (2002) 852-854
11. Al-Ruzzeh S., Mahmoud A., Shah S., et al. Caution with the use of recombinant activated factor VII in treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 83 (2007) 355
12. Dietrich W., and Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg 94 (2002) 1369-1370